What’s Next for Gossamer Bio After $212 Million Financing?SAN DIEGO, October 1, 2023 — Clinical-stage biopharmaceutical company Gossamer Bio, which is focused on the development and…Oct 1, 2023Oct 1, 2023
Armistice Capital Sells Almost Half of Its Thermo Fisher Scientific PositionArmistice Capital LLC, a global hedge fund focused on the consumer and healthcare sectors, recently reduced its stake in medical research…Aug 9, 2023Aug 9, 2023
Armistice Capital Llc Sold The Majority Of Its Lululemon SharesGlobal hedge fund Armistice Capital made headlines when it sold its holdings in Lululemon Athletica Inc. (NASDAQ: LULU). Sources reported…Aug 9, 2023Aug 9, 2023
Prominent Healthcare Hedge Fund Armistice Capital LLC Reduces Stake in eCommerce Giant Shopify by…Armistice Capital LLC, a prominent New York-based hedge fund that specializes in healthcare investment, has shocked the market with its…Jul 18, 2023Jul 18, 2023
Armistice Capital LLC Increases Holdings in Paramount Global by 168.8%Armistice Capital LLC, a leading hedge fund, has significantly increased its holdings in shares of Paramount Global (NASDAQ:PARA) by 168.8%…Jul 18, 2023Jul 18, 2023
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney…$35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving…May 1, 2023May 1, 2023
Sol-Gel Announces Aggregate $22.8NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology…Jan 27, 2023Jan 27, 2023
